IDEXX Laboratories, Inc. $IDXX Shares Sold by 180 Wealth Advisors LLC

180 Wealth Advisors LLC trimmed its position in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 13.8% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 495 shares of the company’s stock after selling 79 shares during the quarter. 180 Wealth Advisors LLC’s holdings in IDEXX Laboratories were worth $266,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also modified their holdings of the company. First Citizens Bank & Trust Co. raised its holdings in shares of IDEXX Laboratories by 36.6% in the 2nd quarter. First Citizens Bank & Trust Co. now owns 19,851 shares of the company’s stock valued at $10,647,000 after purchasing an additional 5,315 shares in the last quarter. Schaper Benz & Wise Investment Counsel Inc. WI raised its holdings in shares of IDEXX Laboratories by 0.7% in the 2nd quarter. Schaper Benz & Wise Investment Counsel Inc. WI now owns 50,173 shares of the company’s stock valued at $26,910,000 after purchasing an additional 339 shares in the last quarter. Strategic Blueprint LLC acquired a new stake in shares of IDEXX Laboratories in the 2nd quarter valued at $244,000. Capital Investment Services of America Inc. raised its holdings in shares of IDEXX Laboratories by 0.8% in the 2nd quarter. Capital Investment Services of America Inc. now owns 39,862 shares of the company’s stock valued at $21,380,000 after purchasing an additional 328 shares in the last quarter. Finally, Ethic Inc. raised its holdings in shares of IDEXX Laboratories by 11.7% in the 2nd quarter. Ethic Inc. now owns 9,668 shares of the company’s stock valued at $5,137,000 after purchasing an additional 1,011 shares in the last quarter. 87.84% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on IDXX shares. UBS Group started coverage on shares of IDEXX Laboratories in a report on Wednesday, October 1st. They issued a “neutral” rating and a $720.00 price objective on the stock. Leerink Partners raised their price objective on shares of IDEXX Laboratories from $580.00 to $600.00 and gave the company an “outperform” rating in a report on Thursday, July 17th. BTIG Research raised their price objective on shares of IDEXX Laboratories from $545.00 to $785.00 and gave the company a “buy” rating in a report on Tuesday, August 5th. Weiss Ratings reaffirmed a “buy (b-)” rating on shares of IDEXX Laboratories in a research report on Saturday. Finally, Morgan Stanley increased their target price on shares of IDEXX Laboratories from $722.00 to $765.00 and gave the company an “overweight” rating in a research report on Friday, August 15th. One research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and four have issued a Hold rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $656.50.

IDEXX Laboratories Trading Up 0.4%

NASDAQ IDXX opened at $640.85 on Friday. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.11 and a quick ratio of 0.79. The firm’s fifty day moving average price is $638.40 and its 200 day moving average price is $559.16. The company has a market capitalization of $51.27 billion, a price-to-earnings ratio of 53.36, a price-to-earnings-growth ratio of 4.15 and a beta of 1.58. IDEXX Laboratories, Inc. has a 12 month low of $356.14 and a 12 month high of $688.12.

IDEXX Laboratories (NASDAQ:IDXX) last issued its quarterly earnings data on Monday, August 4th. The company reported $3.63 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.28 by $0.35. IDEXX Laboratories had a net margin of 24.41% and a return on equity of 64.42%. The company had revenue of $1.11 billion for the quarter, compared to the consensus estimate of $1.06 billion. During the same period last year, the firm posted $2.44 EPS. IDEXX Laboratories’s revenue for the quarter was up 10.6% on a year-over-year basis. IDEXX Laboratories has set its FY 2025 guidance at 12.400-12.760 EPS. On average, sell-side analysts expect that IDEXX Laboratories, Inc. will post 11.93 earnings per share for the current fiscal year.

Insider Activity at IDEXX Laboratories

In other IDEXX Laboratories news, CEO Jonathan Jay Mazelsky sold 29,260 shares of the firm’s stock in a transaction on Wednesday, August 6th. The shares were sold at an average price of $631.98, for a total transaction of $18,491,734.80. Following the transaction, the chief executive officer directly owned 83,311 shares of the company’s stock, valued at approximately $52,650,885.78. This trade represents a 25.99% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, EVP Sharon E. Underberg sold 5,450 shares of the firm’s stock in a transaction on Friday, August 8th. The stock was sold at an average price of $651.60, for a total transaction of $3,551,220.00. Following the transaction, the executive vice president directly owned 6,156 shares in the company, valued at $4,011,249.60. The trade was a 46.96% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 54,057 shares of company stock worth $34,293,468 in the last three months. Company insiders own 0.98% of the company’s stock.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.